Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of M4344 (gartisertib) alone and with carboplatin in advanced solid tumors
NCT02278250Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Jan 2015
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of gartisertib in solid tumor (4 arms), sponsored by EMD Serono. Primary endpoints: Treatment-Emergent Adverse Events up to 124.9 weeks, Grade 3 or 4 Laboratory Abnormalities up to 124.9 weeks and 4 more. Started Jan 2015; status: completed.
02
Drugs
gartisertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02278250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278250.